CELLERYS
Cellerys is a Zurich-based startup conducting research on a therapy to fight multiple sclerosis.
CELLERYS
Industry:
Biotechnology Pharmaceutical
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Status:
Active
More informations about "Cellerys"
About us - cellerys
Reinventing MS therapy. Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint …See details»
Science - cellerys
Reinventing MS therapy. Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint …See details»
Cellerys - Crunchbase Company Profile & Funding
Organization. Cellerys . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. ... Cellerys is a Zurich-based startup conducting research on …See details»
Novartis signs deal that could lead to acquisition of …
Jun 1, 2021 "Novartis will have the option to acquire Cellerys upon completion of a Phase 2 trial in the coming years." Cellerys was founded in 2015 as a University of Zurich spin-out by MS researchers.See details»
Novartis signs partnership agreement with Zurich based startup …
Jul 14, 2021 Novartis has the option to acquire Cellerys in the coming years upon completion of the Phase 2 studies. Cellerys. Cellerys was founded in 2015 as a spin-out from the University …See details»
Novartis acquires option to acquire Zurich-based startup Cellerys
Jul 13, 2021 Novartis has the option to acquire Cellerys upon completion of Phase 2 trials in the coming years. Cellerys was founded in 2015 as a spin-off from the Univer-sity of Zurich by two …See details»
Cellerys signs a cooperation with Novartis - Wyss Zurich
Nov 18, 2021 01-06-2021 – Cellerys, the startup of the ETIMSred project enters into a collaboration with Novartis. The UZH spin-off Cellerys AG is conducting research on an …See details»
Novartis acquires Cellerys - 2021-06-01 - Crunchbase
Jun 1, 2021 Cellerys Cellerys is a Zurich-based startup conducting research on a therapy to fight multiple sclerosis. Acquiring Organization: Novartis Novartis is a healthcare company that …See details»
RED4MS - cellerys
Reinventing MS therapy. Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint accelerator of the University of Zurich and ETH …See details»
Novartis signs deal that could lead to acquisition of Zurich
Jun 1, 2021 "Novartis will have the option to acquire Cellerys upon completion of a Phase 2 trial in the coming years." Cellerys was founded in 2015 as a University of Zurich spin-out by MS …See details»
neogap and cellerys enter collaboration phase II study multiple ...
May 4, 2023 Cellerys was founded in 2015 as a spin-out from the University of Zurich. The company is developing a cell therapy with the goal of inducing antigen-specific immune …See details»
Cellerys AG - startup.ch
Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint accelerator of the …See details»
Novartis inks partnership agreement with Cellerys - startupticker.ch
Apr 6, 2021 For the next phase, Cellerys and Novartis have entered a long-term partnership. "Under the agreement, Novartis will support the development of the CLS12311 therapy the …See details»
Novartis pens buyout pact with fellow Swiss native Cellerys, eyeing ...
Jun 1, 2021 Novartis has signed up to a collab pact and possible buyout deal, should all go to plan, for quiet, little-known Swiss biotech Cellerys. The Zurich-based company is working on …See details»
Cellerys - Products, Competitors, Financials, Employees, …
Cellerys is a biotechnology company focused on developing therapies for immune tolerance, particularly in the context of multiple sclerosis (MS). Use the CB Insights Platform to explore …See details»
News – cellerys
News 14.06.2024 Cellerys AG announces start of immune tolerance trial RED 4 MS trial in multiple sclerosis! We are pleased to announce that we are now screening the first patients for …See details»
CLS-12311 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 The collaboration agreement with Cellerys gives Novartis the option of buying out the former Swiss biotech, which is currently developing CLS12311, a multiple sclerosis drug in …See details»
Cellerys - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Jul 15, 2024 Organization. Cellerys . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 4. Monthly Visits 37. …See details»
Partners - cellerys
Reinventing MS therapy. Cellerys was founded in 2015 as a spin-out from the University of Zurich, where it conducted a successful phase I clinical trial with the support of Wyss Zurich, a joint …See details»
This Slow Cooker Leftover Turkey Gumbo Has Real-Deal Louisiana …
3 days ago After that, good news it's essentially hands-off. Just drop it in the slow cooker and let it do the work for you. Worcestershire sauce provides savory depth, Louisiana-style hot sauce …See details»